A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
← catalyst calendarNCT05888831 · readout in 41 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
20
Countries
Belgium, France, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-06 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BMS-986449
- Drug: Nivolumab — also filed as OPDIVO®, BMS-936558
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Dose-Limiting Toxicities (DLTs)
measured Up to approximately 4 years
Number of participants with Adverse Events (AEs)
measured Up to approximately 4 years
Number of participants with Serious Adverse Events (SAEs)
measured Up to approximately 4 years
Number of participants with AEs leading to discontinuation
measured Up to approximately 4 years
Number of deaths
measured Up to approximately 4 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed